Jan H.M. Schellens
Impact in
- Oncology top 0.01%
- Drug Transport and Resistance Mechanisms
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Pharmacology top 0.02%
- Pharmacogenetics and Drug Metabolism
Papers in
- Oncology 383
- Cancer Treatment and Pharmacology 115
- Colorectal Cancer Treatments and Studies 96
- Drug Transport and Resistance Mechanisms 95
- HER2/EGFR in Cancer Research 37
- Pharmacology 87
- Pharmacogenetics and Drug Metabolism 85
- Co-authors
- J.H. Beijnen (251 shared papers)Hilde Rosing (206 shared papers)Alwin D. R. Huitema (151 shared papers)Dick Pluim (58 shared papers)Alfred H. Schinkel (43 shared papers)Irma Meijerman (30 shared papers)Olaf van Tellingen (43 shared papers)David S. Boss (13 shared papers)
- Journals
- Cancer Chemotherapy and Pharmacology (60 papers)Journal of Chromatography B (53 papers)Investigational New Drugs (47 papers)Clinical Cancer Research (38 papers)Annals of Oncology (35 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Jan H.M. Schellens
810 papers receiving 41.6k citations
Jan H.M. Schellens's Hit Papers
Peers
Comparison fields: 5 of 170
- Oncology 19.9k
- Pharmacology 3.3k
- Cancer Research 3.1k
- Molecular Biology 14.2k
- Pharmaceutical Science 1.2k
Countries citing papers authored by Jan H.M. Schellens
This map shows the geographic impact of Jan H.M. Schellens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan H.M. Schellens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan H.M. Schellens more than expected).
Fields of papers citing papers by Jan H.M. Schellens
This network shows the impact of papers produced by Jan H.M. Schellens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan H.M. Schellens. The network helps show where Jan H.M. Schellens may publish in the future.
Co-authors
The 25 scholars most cited alongside Jan H.M. Schellens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 814 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 2921 |
| 2 | Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Hit paper breakdown → | 2001 | 955 |
| 3 | Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Hit paper breakdown → | 2010 | 805 |
| 4 | A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent Hit paper breakdown → | 2004 | 784 |
| 5 | Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer Hit paper breakdown → | 2017 | 663 |
| 6 | Photodynamic Therapy in Oncology Hit paper breakdown → | 2006 | 645 |
| 7 | Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. | 2002 | 608 |
| 8 | Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies Hit paper breakdown → | 2010 | 591 |
| 9 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update Hit paper breakdown → | 2017 | 479 |
| 10 | Approaching tumour therapy beyond platinum drugs Hit paper breakdown → | 2011 | 470 |
| 11 | 2003 | 441 | |
| 12 | Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors Hit paper breakdown → | 2019 | 427 |
| 13 | 2002 | 389 | |
| 14 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial Hit paper breakdown → | 2020 | 353 |
| 15 | Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy Hit paper breakdown → | 2014 | 338 |
| 16 | Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Hit paper breakdown → | 2018 | 324 |
| 17 | 2005 | 296 | |
| 18 | 2010 | 287 | |
| 19 | 2005 | 278 | |
| 20 | 2015 | 264 |
About Jan H.M. Schellens
Jan H.M. Schellens is a scholar working on Oncology, Pharmacology, Molecular Biology, Hematology and Cancer Research, having authored 814 papers that have together received 42.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (115 papers), Cancer therapeutics and mechanisms (112 papers), Colorectal Cancer Treatments and Studies (96 papers), Drug Transport and Resistance Mechanisms (95 papers), Pharmacogenetics and Drug Metabolism (85 papers), Pharmacological Effects and Toxicity Studies (51 papers), HER2/EGFR in Cancer Research (37 papers) and Lung Cancer Treatments and Mutations (37 papers). The work is most often cited by research in Oncology (19.9k citations), Pharmacology (3.3k citations), Cancer Research (3.1k citations), Molecular Biology (14.2k citations) and Pharmaceutical Science (1.2k citations). Jan H.M. Schellens has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include J.H. Beijnen, Hilde Rosing, Alwin D. R. Huitema, Dick Pluim, Alfred H. Schinkel, Irma Meijerman, Olaf van Tellingen, David S. Boss, Rolf W. Sparidans and Marja Mergui‐Roelvink. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Journal of Chromatography B, Investigational New Drugs, Clinical Cancer Research and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.